Ampicillin
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Ampicillin: From Broad-Spectrum Bacterial Infections to Laryngitis
One-Sentence Summary
Ampicillin is a broad-spectrum aminopenicillin antibiotic with well-established activity against Gram-positive and selected Gram-negative bacteria, widely used globally for respiratory tract, urinary tract, and other susceptible bacterial infections — though currently not registered in the Philippines. The TxGNN model predicts it may be effective for Laryngitis, with 1 clinical trial and 20 publications currently supporting this direction. However, the available evidence is largely indirect, and direct RCT data for ampicillin in laryngitis is absent.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Broad-spectrum bacterial infections (no Philippines registration data available) |
| Predicted New Indication | Laryngitis |
| TxGNN Prediction Score | 99.97% |
| Evidence Level | L4 |
| Philippines Market Status | ✗ Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold (Research Question) |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from local regulatory sources. Based on established pharmacology, Ampicillin is an aminopenicillin that inhibits bacterial cell wall synthesis by covalently binding to penicillin-binding proteins (PBPs), blocking transpeptidation of peptidoglycan chains and triggering bacterial lysis. Its spectrum covers Gram-positive organisms (streptococci, enterococci, Listeria) and selected Gram-negative bacteria including non-β-lactamase-producing Haemophilus influenzae — one of the most common bacterial causes of respiratory tract infections.
Laryngitis can have a bacterial etiology involving pathogens that fall within Ampicillin’s coverage: β-hemolytic Streptococcus, H. influenzae, and Klebsiella rhinoscleromatis (the causative organism of rhinoscleroma). The high TxGNN score (99.97%) likely reflects the knowledge graph’s strong association between Ampicillin and upper airway bacterial infections, making the prediction mechanistically plausible for the bacterial subset of laryngitis cases.
However, three critical limitations temper the clinical significance of this prediction: (1) the vast majority of laryngitis cases are viral in etiology, making antibiotic use appropriate only in culture-confirmed bacterial cases; (2) the sole related clinical trial examines amoxicillin/clavulanate — a related but distinct compound — in a post-marketing surveillance design rather than a prospective RCT; and (3) the 20 identified publications consist predominantly of case reports, epiglottitis case series, and retrospective clinical records without any direct head-to-head RCT evidence for ampicillin in laryngitis.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT01406275 | N/A | Completed | 363 | Post-marketing surveillance of CLAVAMOX® (amoxicillin/clavulanate) pediatric dry syrup in Japanese patients with conditions including laryngitis, tonsillitis, pharyngitis, and others (excluding otitis media). Passive safety/efficacy monitoring under real-world conditions — not a direct ampicillin RCT; inferential value for repurposing decisions is limited |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 39879424 | 2025 | Guideline Quality Assessment | CoDAS | AGREE II quality assessment of clinical guidelines for laryngitis and pharyngitis management; identifies significant methodological gaps in current guideline evidence |
| 25944348 | 2015 | Retrospective Cohort | Otolaryngol Head Neck Surg | Hospital- and physician-level variation in perioperative antibiotic selection for laryngectomy and its association with surgical site infection and wound dehiscence rates |
| 1712371 | 1991 | Clinical Study | J Clin Gastroenterol | Short-term antibiotic treatment in 19 Whipple’s disease patients — includes one patient treated directly with ampicillin 2 g/day with favorable clinical response |
| 35923122 | 2023 | Review/Case Report | Ann Otol Rhinol Laryngol | Historical and modern review of spontaneous laryngeal abscess; modern cases linked to uncontrolled diabetes and immunosuppression; antibiotic therapy remains the cornerstone of management |
| 38145982 | 2024 | Retrospective Cohort | Eur Arch Otorhinolaryngol | Pathogen distribution, drug sensitivity, and antibiotic strategy in neck abscesses with or without diabetes; directly informs antibiotic selection for deep neck and laryngeal infections |
| 30579693 | 2019 | Case Report | Auris Nasus Larynx | Laryngeal actinomycosis after bone marrow transplant in a 14-year-old; successfully resolved with a prolonged course of penicillin-class antibiotics |
| 8651625 | 1996 | Case Series | Ann Otol Rhinol Laryngol | Laryngotracheal manifestations of rhinoscleroma (Klebsiella rhinoscleromatis); early oral tetracycline effective; laryngotracheal disease may require operative intervention in addition to antibiotics |
| 34986973 | 2023 | Case Report | Auris Nasus Larynx | COVID-19 presenting as acute epiglottitis with extensive necrotic laryngeal lesions; illustrates severity spectrum of acute laryngeal infection requiring urgent antibiotic and airway management |
| 3977063 | 1985 | Retrospective Clinical Series | Anaesth Intensive Care | 161 children with acute epiglottitis (1975–1984); 45 complications in 34 patients including 5 deaths; antibiotic therapy is integral to management alongside airway control |
| 12402494 | 2002 | Case Series | Acta Otorrinolaringol Esp | Two cases of paraglottic laryngeal abscess — a rare, life-threatening entity that requires rapid diagnosis and prompt antibiotic treatment to prevent airway compromise |
Philippines Market Information
Ampicillin currently has no registered products in the Philippines. As of the data cutoff (April 4, 2026), there are 0 active authorizations and the drug is not marketed locally. Any clinical use or repurposing initiative would require a full regulatory submission to the Food and Drug Administration of the Philippines (FDA Philippines).
Safety Considerations
Please refer to the package insert for safety information.
Note: Key warnings, contraindications, and drug interaction data were not retrievable at the time of this report (designated as data gaps DG001 and DG002). TFDA/Philippines FDA label PDF extraction and a DrugBank API query are recommended as immediate next steps before any clinical evaluation.
Conclusion and Next Steps
Decision: Hold (Research Question)
Rationale: The available evidence is insufficient to support a repurposing decision for ampicillin in laryngitis. The single related clinical trial evaluated a different compound (amoxicillin/clavulanate) in a passive surveillance design, and the 20 literature references consist predominantly of case reports, retrospective series, and epiglottitis studies lacking direct head-to-head RCT data for ampicillin. The clinical indication for any antibiotic in laryngitis is inherently narrow given the predominantly viral etiology of the condition.
To proceed, the following is needed:
- Safety data: Extract package insert warnings, contraindications, and drug-drug interaction profile from TFDA/Philippines FDA label (currently blocking — DG001)
- MOA data: Query DrugBank API to obtain complete mechanism of action details (currently high-severity gap — DG002)
- Direct clinical evidence: Prospective or retrospective clinical study specifically evaluating ampicillin in culture-confirmed bacterial laryngitis
- Resistance surveillance: Assessment of local antibiotic resistance patterns for relevant laryngeal pathogens (S. pyogenes, H. influenzae, K. rhinoscleromatis) in the Philippines
- Regulatory pathway: Develop Philippines FDA regulatory filing strategy, given zero current local registrations
- Indication refinement: Clarify whether the target is bacterial laryngitis specifically (culture-confirmed) rather than laryngitis as a broad syndrome, to narrow the clinical development scope
⚠️ Disclaimer: This report is intended for research reference purposes only and does not constitute medical advice. Drug repurposing candidates require clinical validation before any therapeutic application.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.